Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
The inhibitory effect of gabexate mesylate, which is used therapeutically in the treatment of pancreatitis and disseminated intravascular coagulation, and as a regional anticoagulant agent for hemodialysis, has been measured on bovine factor Xa, bovine alpha-thrombin, human Lys77-plasmin, human urinary kallikrein, human urokinase, porcine pancreatic beta-kallikrein-B, and bovine beta-trypsin catalyzed hydrolysis of p-nitrophenyl esters of N-alpha-carbobenzoxy-L-arginine and N-alpha-carbobenzoxy-L-lysine. On the basis of enzyme:gabexate mesylate affinities, the serine proteases can be arranged as follows: human urinary kallikrein approximately porcine pancreatic beta-kallikrein-B much less than bovine beta-trypsin approximately bovine factor Xa approximately human Lys77-plasmin approximately human urokinase approximately bovine alpha-thrombin. The mode of binding of gabexate mesylate to the serine proteases conforms to the active-reactive site geometries observed in their complexes with natural and synthetic inhibitors. Differences in gabexate mesylate affinities for these proteases reflect structural differences at their primary specificity subsite, which have been investigated by comparative analysis of amino acid sequences and by computer-graphics techniques.
D000818:Animals; D002417:Cattle; D003196:Computer Graphics; D010450:Endopeptidases; D016670:Gabexate; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D008956:Models, Chemical; D008968:Molecular Conformation; D011480:Protease Inhibitors; D012697:Serine Endopeptidases; D013552:Swine; D013816:Thermodynamics
D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D010450:Endopeptidases; D012697:Serine Endopeptidases